Charles River Laboratories Inte (CRL) Stock Analysis
Healthcare · Diagnostics & Research · NYSE
Charles River Laboratories Inte (CRL) posted $4.02B in revenue for fiscal 2025 (down 0.9% year over year), with a net loss of $144.34M, and has compounded revenue about 6.5%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Charles River Laboratories Inte
Charles River Laboratories Inte has grown revenue from $1.68B to $4.02B over the last 10 fiscal years, compounding about 6.5% a year. The most recent year was down 0.9%, so growth has cooled from its longer-run pace.
Net margin sits at -3.6%, down 4.1 points year over year.
The one thing worth a second look in the filings is currently unprofitable.
Synthesised from Charles River Laboratories Inte's SEC filings — descriptive, not advice. Ask the analyst your own question →
Charles River Laboratories Inte revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.68B | $1.86B | $2.27B | $2.62B | $2.92B | $3.54B | $3.98B | $4.13B | $4.05B | $4.02B |
| Gross profit | $1.40B | $1.57B | — | — | — | — | — | — | — | — |
| Net income | $154.76M | $123.36M | $226.37M | $252.02M | $364.30M | $390.98M | $486.23M | $474.62M | $22.20M | $-144.34M |
| Net margin | 9.2% | 6.6% | 10.0% | 9.6% | 12.5% | 11.0% | 12.2% | 11.5% | 0.5% | -3.6% |
Source: Charles River Laboratories Inte SEC filings (10-K). 18 years of history available in the interactive view.
Charles River Laboratories Inte: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Currently unprofitableThe latest fiscal year was a net loss (net margin -3.6%).
Explore 18 years of Charles River Laboratories Inte financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track CRL in your portfolio →
Charles River Laboratories Inte financial history by metric
Compare Charles River Laboratories Inte with peers
About Charles River Laboratories Inte
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Charles River Laboratories Inte — frequently asked questions
What is Charles River Laboratories Inte's revenue?
Charles River Laboratories Inte (CRL) reported revenue of $4.02B for fiscal year 2025, down 0.9% from the prior year, according to its SEC filings.
Is Charles River Laboratories Inte profitable?
No — CRL reported a net loss of $-144.34M in fiscal 2025.
What is CRL's P/E ratio?
Charles River Laboratories Inte trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Charles River Laboratories Inte growing?
CRL's revenue grew at roughly 6.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Charles River Laboratories Inte have?
As of fiscal year 2025, CRL carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Charles River Laboratories Inte's market cap?
Charles River Laboratories Inte (CRL) has a market capitalization of about $0, based on the latest data in our nightly-refreshed cache.
When does Charles River Laboratories Inte's fiscal year end?
CRL's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-27.
Where does this data come from?
All figures are computed from Charles River Laboratories Inte's official SEC filings (10-K and 10-Q), covering 18 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.